Frozen Platelets in the Treatmentof Traumatic or Vascular Bleeding

Launched by ALRIJNE ZIEKENHUIS LEIDERDORP · Aug 15, 2022

Keywords

ClinConnect Summary

The MAssive transfusion of Frozen bloOD (MAFOD) trial is a clinical study that aims to find out how effective and safe frozen platelets, kept at very low temperatures, are for treating patients with serious bleeding from trauma or blood vessel injuries. For many years, the Netherlands Armed Forces have used these frozen platelets successfully in emergency situations, but there hasn't been enough high-quality research to confirm how well they work compared to regular platelets that are stored at room temperature. This trial will compare the effects of both types of platelets on patients who need a lot of blood transfusions.

To be eligible for the study, participants must be 12 years or older, be alive when they arrive at the hospital, and need a large amount of platelet transfusion. Pregnant individuals will not be able to participate. If someone joins the trial, they will receive either the frozen platelets or the standard ones as part of their treatment. This study is important because it could help improve how we manage severe bleeding in emergency situations, ultimately saving lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients of 12 years or older
• • Alive at hospital presentation
• • Requiring massive transfusion including platelets
• • Signed (deferred) consent
• Exclusion Criteria:
• • Known pregnancy